Kaken PharmaceutialKAKEN PHARMACEUTIAL CO., LTD.4521東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥1 for every ¥100 of sales at the operating level. Revenue changed -18.3% from the prior year, operating profit -104.3%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 12.6% | 0.46× | 5.8% | 1.24× | 7.2% |
| 2023 | 7.5% | 0.44× | 3.3% | 1.25× | 4.1% |
| 2024 | 11.1% | 0.43× | 4.7% | 1.27× | 6.0% |
| 2025 | 14.8% | 0.52× | 7.6% | 1.31× | 10.0% |
| 2026 | 2.8% | 0.41× | 1.2% | 1.32× | 1.5% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 76,034 | 72,984 | 72,044 | 94,035 | 76,871 |
| Cost of revenue | 34,458 | 33,428 | 33,505 | 35,502 | 36,879 |
| Gross profit | 41,575 | 39,555 | 38,539 | 58,532 | 39,991 |
| SG&A | 24,511 | 31,556 | 29,025 | 37,497 | 40,891 |
| Operating income | 17,064 | 7,998 | 9,513 | 21,034 | -899 |
| Pretax income | 13,885 | 6,817 | 9,796 | 19,435 | 2,313 |
| Income tax | 4,336 | 1,377 | 1,770 | 5,490 | 168 |
| Net income attributable to owners | 9,549 | 5,440 | 8,025 | 13,945 | 2,144 |
| Operating margin | 22.4% | 11.0% | 13.2% | 22.4% | -1.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥74.6B | ¥74.3B | ¥65.3B | ¥70.1B | ¥50.7B |
| Total assets | ¥165.2B | ¥166.3B | ¥171.6B | ¥193.4B | ¥178.2B |
| Net assets | ¥138.3B | ¥136.8B | ¥143.8B | ¥152.6B | ¥147.6B |
| Share capital | ¥23.9B | ¥23.9B | ¥23.9B | ¥23.9B | ¥23.9B |
| Property, plant and equipment | ¥25.7B | ¥25.5B | ¥25.4B | ¥27.6B | ¥27.1B |
| Intangible assets excluding goodwill | ¥8.24B | ¥6.74B | ¥7.46B | ¥22.2B | ¥24.3B |
| Goodwill | ¥312M | ¥230M | ¥937M | ¥5.46B | ¥5.4B |
| Investment securities | ¥17.1B | ¥17.5B | ¥20.5B | ¥18.9B | ¥18.7B |
| Current assets | ¥110.6B | ¥109.9B | ¥107B | ¥111.4B | ¥94.1B |
| Current liabilities | ¥19B | ¥20.8B | ¥19B | ¥30.4B | ¥20.8B |
| Trade payables | ¥5.86B | ¥6.13B | ¥6.98B | ¥8.19B | ¥7.43B |
| Short-term borrowings | ¥3.85B | ¥3.85B | ¥3.85B | ¥3.85B | ¥3.85B |
| Total liabilities | ¥26.9B | ¥29.5B | ¥27.9B | ¥40.7B | ¥30.6B |
| Non-controlling interests | ¥578M | ¥578M | — | — | — |
| Equity attributable to owners of parent | ¥132.9B | ¥131.4B | ¥135.2B | ¥143.8B | ¥137.1B |
| Retained earnings | ¥126.3B | ¥126.1B | ¥128.5B | ¥135.2B | ¥125.6B |
| Treasury stock | -¥28.7B | -¥30B | -¥28.6B | -¥28.2B | -¥23.8B |
EDINET (FSA Japan)
有価証券報告書－第106期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第105期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第104期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第103期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第102期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第101期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 51 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.